|
Apr 29
|
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
|
|
Apr 10
|
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
|
|
Apr 8
|
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 28
|
PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
|
|
Mar 28
|
Q4 2023 PAVmed Inc Earnings Call
|
|
Mar 27
|
PAVmed Full Year 2023 Earnings: EPS Beats Expectations
|
|
Mar 26
|
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 21
|
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
|
|
Mar 21
|
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
|
|
Mar 20
|
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
|
|
Mar 13
|
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
|
|
Mar 12
|
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
|
|
Feb 16
|
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
|
|
Feb 15
|
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
|
|
Dec 12
|
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
|
|
Dec 11
|
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
|
|
Dec 4
|
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
|
|
Dec 1
|
Top Penny Stocks for Q4 2023
|
|
Nov 16
|
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call Transcript
|
|
Nov 16
|
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
|